SAM
RLAY icon

Smartleaf Asset Management’s Relay Therapeutics RLAY Stock Holding History

Smartleaf Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87.2K Hold
4,415
– – ﹤0.01% 1243
2026
Q1 		$41.3K Sell
4,415
-11
-0.2% -$98 ﹤0.01% 1553
2025
Q4 		$37K Buy
4,426
+3,287
+289% +$23.5K ﹤0.01% 1696
2025
Q3 		$5.91K Buy
1,139
+1,023
+882% +$3.9K ﹤0.01% 2325
2025
Q2 		$382 Sell
116
-813
-88% -$2.42K ﹤0.01% 2618
2025
Q1 		$2.53K Buy
929
+832
+858% +$3.26K ﹤0.01% 2409
2024
Q4 		$405 Sell
97
-957
-91% -$5.21K ﹤0.01% 2808
2024
Q3 		$7.86K Buy
1,054
+748
+244% +$5.59K ﹤0.01% 1899
2024
Q2 		$1.93K Buy
+306
New +$2.09K ﹤0.01% 2242

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Smartleaf Asset Management's RLAY Position: Q2 2026 in Review

Smartleaf Asset Management held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 4,415 shares worth $87.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1243.

Smartleaf Asset Management first reported a position in RLAY in Q2 2024 and has held it in 9 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Smartleaf Asset Management held 4,415 shares of Relay Therapeutics worth $87.2K as of Q2 2026.
  • Smartleaf Asset Management left its Relay Therapeutics share count unchanged in Q2 2026.
  • Relay Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1243 holding.
  • Smartleaf Asset Management first reported a position in Relay Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.